Wallife, founded in 2020 by Fabio Sbianchi and Maria Enrica Angelone and based in Rome, develops insurance products to cover new and evolving risks that conventional insurers have not addressed. Its areas of focus include genetic manipulation (preservation of biological material and genetic identity), biohacking (prostheses and implantable medical devices), and the use of digital biometric data such as fingerprints and facial recognition. The company aims to build the world’s first firm able to provide safety and protection answers for these emerging and unknown risks. Wallife plans to use recent proceeds to expand international growth, develop new insurance products, strengthen its technological infrastructure, and grow its team. The company also intends to continue research activities through its community of innovators and risk hunters. Financially, Wallife completed a €12M Series A and ranks seventh in Europe in the insurtech sector by Series A value, per Crunchbase. Wallife, founded in 2021 and based in Rome, focuses on protecting individuals from risks arising from technological innovation and scientific progress across genetics, biometrics, and biohacking. Its product work targets preservation of biological material and genetic identity, biometric privacy (fingerprints, facial recognition), and risks from implantable devices and prostheses. The company is led by CEO Maria Enrica Angelone and was founded by Fabio Sbianchi, who previously founded Octo Telematics. Wallife plans to use new capital to study and patent novel protection approaches and to develop its insurance platform. Management plans a second round of investment in 2022 to accompany the launch and development of new products. The company presented this strategy alongside its initial fundraising to support product and IP development.

Total raised

$17M

Funding rounds

2

Latest round

Series A

Latest activity

Jul 2022